There has never been a study that demonstrated the HPV vaccines reduced incidence of cancer. The vaccine was fast tracked simply on the basis that it created antibodies to the HPV strain. There are studies that show the vaccine actually increases your chance of many other cancer causing viruses.
Studies:
Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants.
Human papillomavirus vaccine and systemic lupus erythematosus.
On the relationship between human papilloma virus vaccine and autoimmune diseases.
Premature ovarian failure 3 years after menarche in 16 year old girl following HPV vaccination.
"We retrospectively described a case series including 18 girls (aged 12–24 years) referred to our “Second Opinion Medical Network” for the evaluation of “neuropathy with autonomic dysfunction” after HPV vaccination. All girls complained of long-lasting and invalidating somatoform symptoms (including asthenia, headache, cognitive dysfunctions, myalgia, sinus tachycardia and skin rashes) that have developed 1–5 days (n = 11), 5–15 days (n = 5) and 15–20 days (n = 2) after the vaccination. These cases can be included in the recently described immune dysfunction named autoimmune/inflammatory syndrome induced by adjuvants (ASIA)."
"958 hospitalizations
+ 19,351 ED (emergency room visits)
= 20,309 serious adverse events"
+ 19,351 ED (emergency room visits)
= 20,309 serious adverse events"
So 20,000 of 195,000 girls who got HPV vaccines. ---- OR 10% ---- had a SERIOUS enough reaction that it warranted a trip to the ER within 42 days of vaccination.
"Rates of AEFI [adverse reactions] after HPV immunization in Alberta are low and consistent with types of events seen elsewhere."
Behavioral abnormalities in female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil.
Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males.
Expression of p16INK4A in Cervical Precancerous Lesions unlikely to be preventable by HPV Vaccines
HPV:
Molecular mimicry, original antigen sin, and Quantifying the possible cross-reactivity risk of an HPV16 vaccine.
This study would explain again directly the HPV vaccine caused autoimmune disorders that have been known of and as well possibly some of the adverse reactions and un-recovered from outcomes related to both HPV vaccines, Gardasil and Cervarix.
The standard pharma directed version immunologists have simply ignored the issue of molecular mimicry, in regard to the development and use of vaccines. As well the second most irresponsible form of neglect that immunologists ignore in regard to vaccine production, is the issue and concept known as original antigenic sin. The original antigenic sin issue only involves vaccine deriving immunity, and not natural immunity.
Quantifying the possible cross-reactivity risk of an HPV16 vaccine.
Kanduc D. J Exp Ther Oncol. 2009.
Kanduc D. J Exp Ther Oncol. 2009.
Abstract
BACKGROUND: The potential adverse events associated with vaccination for infectious diseases underscore the need for effective analysis and definition of possible vaccine side effects. Using the HPV16 proteome as a model, we quantified the actual and theoretical risks of anti-HPV16 vaccination, and defined the potential disease spectrum derived from concomitant cross-reactions with the human organism.
METHODS: We searched the primary sequence of the HPV16 proteome for heptamer aminoacid sequences shared with human proteins using the Protein International Resource database.
RESULTS: The human proteome contains 82 heptapeptides and two octapeptides found in HPV16. The viral matches are spread among proteins involved in fundamental processes, such as cell differentiation and growth and neurosensory regulation. The human proteins containing the HPV16-derived heptamers include cell-adhesion molecules, leukocyte differentiation antigens, enzymes, proteins associated with spermatogenesis, transcription factors, and neuronal antigens. The number of viral matches and their locations make the occurrence of side autoimmune cross-reactions in the human host following HPV16-based vaccination almost unavoidable.
CONCLUSIONS: Any antigen-based vaccine needs to be carefully and thoroughly designed and critically screened for potential side effects by comparing sequence similarity at the molecular level.
http://www.ncbi.nlm.nih.gov/pubmed/19827272/?ncbi_mmode=std (link as it stands in Pubmed)
Molecular Mimicry as a Mechanism of Autoimmune Disease:
Abstract
A variety of mechanisms have been suggested as the means by which infections can initiate and/or exacerbate autoimmune diseases. One mechanism is molecular mimicry, where a foreign antigen shares sequence or structural similarities with self-antigens. Molecular mimicry has typically been characterized on an antibody or T cell level. However, structural relatedness between pathogen and self does not account for T cell activation in a number of autoimmune diseases. A proposed mechanism that could have been misinterpreted for molecular mimicry is the expression of dual T cell receptors (TCR) on a single T cell. These T cells have dual reactivity to both foreign and self-antigens leaving the host vulnerable to foreign insults capable of triggering an autoimmune response. In this review, we briefly discuss what is known about molecular mimicry followed by a discussion of the current understanding of dual TCRs. Finally, we discuss three mechanisms, including molecular mimicry, dual TCRs and chimeric TCRs, by which dual reactivity of the T cell may play a role in autoimmune diseases.
A variety of mechanisms have been suggested as the means by which infections can initiate and/or exacerbate autoimmune diseases. One mechanism is molecular mimicry, where a foreign antigen shares sequence or structural similarities with self-antigens. Molecular mimicry has typically been characterized on an antibody or T cell level. However, structural relatedness between pathogen and self does not account for T cell activation in a number of autoimmune diseases. A proposed mechanism that could have been misinterpreted for molecular mimicry is the expression of dual T cell receptors (TCR) on a single T cell. These T cells have dual reactivity to both foreign and self-antigens leaving the host vulnerable to foreign insults capable of triggering an autoimmune response. In this review, we briefly discuss what is known about molecular mimicry followed by a discussion of the current understanding of dual TCRs. Finally, we discuss three mechanisms, including molecular mimicry, dual TCRs and chimeric TCRs, by which dual reactivity of the T cell may play a role in autoimmune diseases.
Original Antigenic Sin Committed by Vaccination:
By Suzanne Humphries, MD and Roman Bystrianyk – VRAN Newsletter, Fall 2013
http://vaccinechoicecanada.com/…/original-antigenic-sin-co…/
http://vaccinechoicecanada.com/…/original-antigenic-sin-co…/
Gardasil
Updated, augmented vaccines compete with original antigenic sin - Gardasil
Updated, augmented vaccines compete with original antigenic sin - Gardasil
In late December 2014, Sony Salzman, a 25-year-old living in New York City, heard about the approval of Gardasil 9, the latest human papillomavirus (HPV) vaccine created by Merck, and called her gynecologist to ask about the vaccine. Having been vaccinated eight years ago with the previous version, simply called Gardasil, Salzman was interested in receiving the improved version of the vaccine. “But the folks at the doctor’s office had no idea there was even a new version,” Salzman says.
Chalking their ignorance up to the relative newness of the vaccine—it had only been approved by the US Food and Drug Administration (FDA) on 10 December—Salzman waited and then asked again in
April 2015. “I didn’t get a very clear answer on whether I could get the vaccine,” Salzman says. “
April 2015. “I didn’t get a very clear answer on whether I could get the vaccine,” Salzman says. “
What worries some researchers is that individuals who already received vaccination against HPV will not respond to the augmented vaccine version with more strains because of an immunological concept known as ‘original antigenic sin.’
Gardasil challenge When it comes to the label recommendation for revaccination with Gardasil 9, some questions loom. In February, the ACIP voted to recommend Gardasil 9 as one of three possible vaccines a person could get to help prevent HPV infection or one of the cancers caused by the virus. However, the ACIP meeting in February was cut short owing to weather concerns, so the discussion surrounding revaccination was postponed.
Consequently, the topic of revaccination with Gardasil 9 may come up at the end of June when the ACIP will have the second of its three annual meetings in Atlanta.
The current indication for Gardasil 9, which was approved by the FDA in December 2014, is for boys and girls who have never been vaccinated with any type of HPV vaccine before.
Merck has tested Gardasil 9 in girls and women who have already received the older, quadrivalent version of Gardasil, but so far these tests have only looked at safety and immunogenicity.
Preliminary unpublished results from this trial showed that the production of antibodies against the four viral types common to both versions of the vaccine increased slightly in this group compared with those who received Gardasil 9 and had never been previously immunized against HPV. However, antibody titers against the five added viral strains in Gardasil 9 among the former group were only 25% and 63% of that seen in people who received Gardasil 9 alone.
Merck is reluctant to provide advice on revaccination on the basis of these preliminary results. “We don’t know what [the reduced antibody titer] means,” Vichnin says. “This information is provided to physicians and patients, and it’s an individual decision.”
The ACIP has also hesitated to make a recommendation. “There’s some data but it’s mostly safety data,” Markowitz says. “But there’s not an indication for revaccination on the label [of the vaccine].” There have been cost-effectiveness data collected by the CDC but they haven’t been formally presented yet.
Read more:
Death after Quadrivalent Human Papillomavirus (HPV) Vaccination: Causal or Coincidental?
Conclusions: Our study suggests that HPV vaccines containing HPV-16L1 antigens pose an inherent risk for triggering potentially fatal autoimmune vasculopathies.
Nordic Cochrane Research Center Files Complaint About Scientific Misconduct, Secrecy in HPV Vaccine Probe:
Nordic Cochrane Center, a Danish research and information center is challenging the European Medicines Agency’s (EMA) 2015 report on human papillomavirus (HPV) vaccines and the EMA’s position that HPV vaccine benefits outweigh the risks. After numerous reports of HPV vaccine-related brain and immune system injuries and deaths, the Danish Health and Medicines Authority asked the EMA to conduct the probe into HPV vaccine safety, but prominent physicians in the country are not convinced about the EMA’s conclusions downplaying the vaccine’s risks. On May 26, 2016, the Nordic Cochrane Center filed an official complaint charging the EMA with “maladministration” and citing flaws throughout the agency’s report. The EMA replied that it has received the complain and will respond after carefully considering all the issues raised by the research group. The Nordic Cochrane Center is an independent research and information center that is part of Cochrane, an international network of individuals and institutions committed to preparing, maintaining, and disseminating systematic reviews of the effects of health care.
HPV vaccine linked to deaths:
HPV Vaccine Can Make You Susceptible to More Serious Strains of HPV.
Women Vaccinated for HPV May Be at Higher Risk of HPV Infection:
In an analysis of nearly 600 women between the ages of 20 and 26, 60 percent of those who had received the original Gardasil vaccine, which protects against only four strains (types) of HPV (6,11,16,18), had a higher risk of being infected with another non-vaccine HPV virus strain.
The unvaccinated women had lower rates of the non-vaccine high-risk strains of HPV, which suggests getting vaccinated may make you more susceptible to being infected with other strains of HPV.
The researchers' solution to the problem was to suggest women who already have gotten three doses of the original four-strain Gardasil vaccine now get another shot of a new Gardasil vaccine, which contains nine different HPV strains.
In December 2014, the US Food and Drug Administration (FDA) approved Gardasil 9 that includes five additional HPV types (31, 33, 45, 52, 58) not found in the original vaccine. So if you have already received one or more doses of the original Gardasil vaccine, you may actually be at a higher risk of being infected with the five additional HPV types than if you had never been vaccinated at all.
And if you're already infected with one of the four to nine types of HPV viruses in either the original or new Gardasil vaccines, getting vaccinated will not eliminate the infection. Not to mention, there are more than 100 different strains of HPV, 30 of which are sexually transmitted, and about 15 of them have been associated with development of cancer but only IF HPV infection persists over a long period of time and regular pap screen tests are not conducted to identify and treat pre-cancerous cervical lesions.
Gardasil's Effectiveness Seriously Questioned:
In 2012, a systematic review of pre- and post-licensure trials of the HPV vaccine by researchers at the University of British Columbia showed that the vaccine's effectiveness is not only overstated (through the use of selective reporting or "cherry picking" data) but also unproven. In the summary of the clinical trial review, the authors stated quite clearly:
The Risks of HPV Vaccine Are Significant.
By mid-March 2015, the HPV vaccine Gardasil had generated more than 35,000 adverse reaction reports to the US government, including more than 200 deaths.
This is probably a gross underestimate, because, although a federal law was passed in 1986 (the National Childhood Vaccine Injury Act) mandating that doctors and other vaccine providers report serious health problems or deaths that occur after vaccination to VAERS, there are no legal penalties for vaccine providers not reporting and it is estimated that perhaps less than 10 percent of the vaccine adverse events that do occur are reported to VAERS.
Health problems associated with the Gardasil vaccine include immune-mediated inflammatory neurodegenerative disorders, suggesting that something is causing the immune system to overreact in a detrimental way, sometimes fatally. A growing body of medical literature demonstrates that the HPV vaccine is linked to nervous and immune system disorders in some young women and girls.
In one case study published in the Journal of Investigative Medicine,10 researchers described the case of a 14-year-old girl who developed postural orthostatic tachycardia syndrome (POTS) with chronic fatigue two months following Gardasil vaccination.
POTS is a disorder of the autonomic nervous system, which controls functions in your body such as your heart rate, balance, digestion, bladder control, and sleep. While rare, incidence of POTS appears to be increasing and emerging evidence suggests it may be an autoimmune disorder, in which your immune system mistakenly attacks your own body.
In the case study, POTS fulfilled the criteria for a condition known as autoimmune/auto-inflammatory syndrome induced by adjuvants (ASIA), highlighting the underlying mechanisms of how vaccines, and particularly their adjuvants (such as aluminum), may be triggering disease. Gardasil contains an aluminum adjuvant, which is designed to hyper-stimulate the immune system to provoke a strong antibody response.
A second study, published in the European Journal of Neurology, 11 described six patients who developed POTS from six days to two months following HPV vaccination. In addition, deadly blood clots, acute respiratory failure, cardiac arrest and "sudden death due to unknown causes" have all occurred in girls after they've received the Gardasil vaccine.
Mainstream news sources:
Read more:
Breaking News: Gardasil® HPV DNA discovered in post-mortem samples
http://sanevax.org/breaking-news-gardasil-hpv-dna-discover…/
http://sanevax.org/breaking-news-gardasil-hpv-dna-discover…/
Tens of Thousands of Adverse Reactions to this Popular Vaccine Being Labelled “A Coincidence”
HPV Vaccine Insert Information:
Human papillomavirus (HPV)- Given at 11-26 years (3 doses)
HPV Vaccine Ingredients:
HPV (Cervarix)- vitamins, amino acids, lipids, mineral salts, aluminum hydroxide, sodium dihydrogen phosphate dihydrate, insect cell and viral protein, 3-0-desacyl-4' Monophosphoryl lipid
HPV (Gardasil)- yeast protein, vitamins, amino acids, mineral salts, carbohydrates, amorphous aluminum hydroxyphosphate sulfate, L-histidine, polysorbate 80, sodium borate
HPV (Cervarix)- extreme pain, headache, nasopharyngitis, influenza, dizziness, upper respiratory infection, dysmenorrhea, chlamydia infection, pharyngitis, injection site bruising, vaginal infection, back pain, UTI, arthritis, celiac disease, dermatomyositis, diabetes, hyperthyroidism, hypothyroidism, inflammatory bowel disease, psoriasis, death, allergies, vitiligo, seizures
HPV (Gardasil)- headache, fever, nausea, arthritis, death, autoimmune thyroiditis, celiac disease, inflammatory bowel disease, multiple sclerosis, nephritis, pigmentation disorder, diabetes, chills, fatigue, malaise, autoimmune disease, seizures, cellulitis, deep venous thrombosis
23 page package insert from the manufacturer:
Ingredients lists:
